Clearing harmful sugar-related toxins to protect brain cells and memory
Role of clearance of toxic metabolites in mitochondrial and tau pathology
This research tests whether boosting the brain's cleanup of sugar-related toxins can protect mitochondria, reduce tau-related damage, and help preserve memory in people with Alzheimer's disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11092147 on NIH RePORTER |
What this research studies
You may hear about toxic sugar-linked molecules called methylglyoxal and advanced glycation end products (AGEs) that build up with age and can harm brain mitochondria and synapses. Researchers will focus on an enzyme named GLO1 that clears these toxins, measure toxin levels in blood, and link those markers to mitochondrial and synaptic health. The work combines laboratory experiments with analyses that connect blood metabolites to brain tau changes, inflammation, and memory function. Overall the team aims to find whether increasing GLO1 activity can lower toxic metabolites, reduce tau pathology, and slow cognitive decline.
Who could benefit from this research
Good fit: People with Alzheimer's disease or related dementias, especially older adults showing cognitive decline or elevated AGE/methylglyoxal markers, would be most relevant for this research.
Not a fit: Patients whose cognitive problems are caused by non-AD conditions or who do not have elevated AGE/methylglyoxal levels may be less likely to benefit from this approach.
Why it matters
Potential benefit: If successful, this work could lead to new treatments or blood-based tests that lower harmful metabolites, protect brain cells, and slow memory loss in Alzheimer's and related dementias.
How similar studies have performed: Prior preclinical studies link AGEs/methylglyoxal to neuronal damage and suggest GLO1 can reduce toxicity, but direct evidence that boosting GLO1 reduces tau pathology and improves cognition in AD remains limited.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Yan, Shirley Shidu — Columbia University Health Sciences
- Study coordinator: Yan, Shirley Shidu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.